博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300294 博雅生物

已收盘 09-02 15:00:00

{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":14.55,"timestamp":1788332607000,"preClose":14.89,"halted":0,"volume":5477821,"delay":0,"changeRate":-0.0228,"floatShares":504000000,"shares":504000000,"eps":-0.1219,"marketStatus":"已收盘","change":-0.34,"latestTime":"09-02 15:00:00","open":14.86,"high":14.87,"low":14.52,"amount":80014200,"amplitude":0.0235,"askPrice":14.56,"askSize":5,"bidPrice":14.55,"bidSize":29,"shortable":0,"etf":0,"ttmEps":-0.1219,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"adjPreClose":14.89,"symbolType":"stock","openAndCloseTimeList":[[1788312600000,1788319800000],[1788325200000,1788332400000]],"highLimit":16.38,"lowLimit":13.4,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.01,"roa":"--","roe":"0.69%","epsLYR":0.22,"committee":0.696745,"marketValue":7337000000,"turnoverRate":0.0109,"status":1,"floatMarketCap":7337000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2664000008","title":"股市必读：博雅生物（300294）8月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664000008?lang=zh_cn&edition=full","pubTime":"2026-09-01 03:26","pubTimestamp":1788204373,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，博雅生物报收于14.69元，下跌1.54%，换手率0.89%，成交量4.49万手，成交额6611.59万元。董秘最新回复投资者： 公司的业绩为什么越来越差，以后有什么举措来改善董秘： 您好，感谢您对本公司的关注。自2025年以来，血液制品行业面临多重政策叠加带来的阶段性压力。投资者： 博雅生物经过华润5年的赋能，从160亿以上市值，到现在不足80亿。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226553","title":"博雅生物：聚焦血液制品核心业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661226553?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:03","pubTimestamp":1787554991,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘血制品行业长期刚性增长逻辑在那些地方？博雅生物重点在那个方向发展？博雅生物回复：您好，感谢您对公司的关注。血液制品是国家战略储备类生物医药产品，也被纳入生物安全管控范畴。血液制品行业是国家生物安全战略的核心组成部分、公共卫生应急体系的战略储备、高端生物医药产业的关键赛道，具有不可替代的重要性。公司围绕成为国内乃至世界一流血液制品企业的战略愿景，聚焦血液制品核心业务。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400014363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661269778","title":"博雅生物(300294)8月10日股东户数3.25万户，较上期增加0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661269778","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661269778?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:46","pubTimestamp":1787305605,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2026年8月10日公司股东户数为3.25万户，较7月20日增加292.0户，增幅为0.91%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至8月10日，生物制品行业平均股东户数为3.53万户。从股价来看，2026年7月20日至2026年8月10日，博雅生物区间跌幅为0.13%，在此期间股东户数增加292.0户，增幅为0.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402271","title":"8月20日博雅生物涨6.11%，创金合信启富优选股票发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402271?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:42","pubTimestamp":1787215345,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日博雅生物涨6.11%，收盘报15.8元，换手率4.16%，成交量20.98万手，成交额3.36亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为创金合信基金的创金合信启富优选股票发起A。创金合信启富优选股票发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660538494","title":"股市必读：博雅生物（300294）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660538494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660538494?lang=zh_cn&edition=full","pubTime":"2026-08-19 03:29","pubTimestamp":1787081349,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，博雅生物报收于15.15元，下跌1.5%，换手率1.37%，成交量6.93万手，成交额1.05亿元。董秘最新回复投资者： 您好！请问截至8月10日公司股东人数是多少，谢谢董秘： 您好，感谢您对本公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900003493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660946529","title":"博雅生物：公司2026年8月10日股东人数为32,521户","url":"https://stock-news.laohu8.com/highlight/detail?id=2660946529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660946529?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:33","pubTimestamp":1787045615,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至8月10日公司股东人数是多少，谢谢博雅生物回复：您好，感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据，公司2026年8月10日含信用账户合并名册的股东人数为32,521户。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659794161","title":"股市必读：博雅生物（300294）8月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659794161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659794161?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:34","pubTimestamp":1786646053,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，博雅生物报收于15.72元，上涨0.0%，换手率1.63%，成交量8.22万手，成交额1.3亿元。董秘最新回复投资者： 公司股价持续性下跌，跟管理层关系重大，公司没有市值管理吗？公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司将根据产品研发的进展情况，及时披露相关信息。当日关注点交易信息汇总：8月13日主力资金净流入67.2万元，占总成交额0.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670089","title":"股市必读：博雅生物（300294）8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670089?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:58","pubTimestamp":1786298292,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，博雅生物报收于15.6元，上涨1.3%，换手率1.51%，成交量7.62万手，成交额1.17亿元。公司高度重视应收账款回款风险，围绕制度建设、客户管控、业务闭环落地全链条管控举措。公司预计2026年与控股股东关联方日常性交易不超过43,435.40万元。当日关注点交易信息汇总：8月7日主力资金净流入552.78万元，占总成交额4.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611524","title":"博雅生物：坚持长期主义，聚焦主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657611524?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:30","pubTimestamp":1786095040,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物08月07日在投资者关系平台上答复投资者关心的问题。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司一直坚持长期主义，围绕战略目标，聚焦主业，强化核心竞争力，结合政策环境、市场环境等制定适合公司发展的经营策略，努力做好经营管理，提升经营质量与盈利能力，促进公司健康可持续发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657115226","title":"博雅生物：公司预计2026年与控股股东关联方日常性交易不超过43,435.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657115226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657115226?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:30","pubTimestamp":1786095040,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问管理层博雅生物供货华润医疗有多大？市占率有多少？未来有没可能提高供货比率？博雅生物回复：您好，感谢您对本公司的关注。公司借助控股股东的资源，强化渠道建设。公司预计2026年与控股股东关联方日常性交易不超过43,435.40万元。当年具体的交易金额具体届时请参阅定期报告。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657115476","title":"博雅生物：推动应收账款结构优化、经营性现金流提质向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2657115476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657115476?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:30","pubTimestamp":1786095039,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物08月07日在投资者关系平台上答复投资者关心的问题。公司高度重视应收账款回款风险，围绕制度建设、客户管控、业务闭环落地全链条管控举措。现阶段锚定授信风险管控、终端市场深耕、运营费用压降等重点工作，推动应收账款结构优化、经营性现金流提质向好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","159399","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683029","title":"博雅生物(300294.SZ)：达拉特旗浆站获得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683029","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657683029?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:55","pubTimestamp":1786002950,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)发布公告，近日，公司控股子公司达拉特旗博雅单采血浆有限公司(简称达拉特旗浆站)获得内蒙古自治区卫生健康委员会颁发的《单采血浆许可证》，采浆范围为达拉特旗区域内，有效期限2026年07月17日至2028年07月16日。该事项有利于提升公司原料血浆供应能力，将对公司长期发展具有积极作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0197","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356292","title":"博雅生物：持续推进“引进来、走出去、强合作”的国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655356292?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:36","pubTimestamp":1785486979,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：东南亚注册门槛偏低，依托华人渠道发挥价格优势，博雅生物下半年有希望出口东南亚市场吗？博雅生物回复：您好，感谢您对本公司的关注。公司持续推进“引进来、走出去、强合作”的国际化战略，有序推进国际合作。公司经营情况及财务状况等信息，请以公司公告为准。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100027356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884941","title":"股市必读：博雅生物（300294）7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655884941?lang=zh_cn&edition=full","pubTime":"2026-07-29 02:23","pubTimestamp":1785262990,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，博雅生物报收于14.78元，上涨0.34%，换手率0.93%，成交量4.68万手，成交额6863.15万元。董秘最新回复投资者： 贵公司股价长期下跌，且较同行企业下跌幅度大，反弹幅度小，公司有从资金方面提振股价的措施吗？博雅生物作为央企子公司是否通过股东增持、股份回购等方式，向市场传递积极信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900001481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654070944","title":"博雅生物：公司2026年7月20日股东人数为32,229户","url":"https://stock-news.laohu8.com/highlight/detail?id=2654070944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654070944?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:21","pubTimestamp":1785230469,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：公司最近的股东数量是多少？博雅生物回复：您好，感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据，公司2026年7月20日含信用账户合并名册的股东人数为32,229户。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800028056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653202770","title":"股市必读：博雅生物（300294）7月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653202770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653202770?lang=zh_cn&edition=full","pubTime":"2026-07-22 02:10","pubTimestamp":1784657453,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，博雅生物报收于15.4元，下跌2.35%，换手率1.66%，成交量8.36万手，成交额1.3亿元。董秘最新回复投资者： 近期两大央企宣布增持中央企业股票，坚决维护资本市场平稳运行。博雅生物作为国有企业，管理层是否坚决维护公司市值，看好企业自身发展？当日关注点交易信息汇总：7月21日主力资金净流出318.94万元，游资资金净流入600.86万元，散户资金净流出281.92万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200002675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653927199","title":"博雅生物：坚持长期主义，聚焦主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653927199?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:00","pubTimestamp":1784631650,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物07月21日在投资者关系平台上答复投资者关心的问题。博雅生物作为国有企业，管理层是否坚决维护公司市值，看好企业自身发展？公司一直坚持长期主义，围绕战略目标，聚焦主业，强化核心竞争力，结合政策环境、市场环境等制定适合公司发展的经营策略，努力做好经营管理，提升经营质量与盈利能力，促进公司健康可持续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100037850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652295236","title":"博雅生物(300294.SZ)：人血管性血友病因子工艺升级后重新获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652295236","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652295236?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:22","pubTimestamp":1784535724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)发布公告，近日，公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发的人血管性血友病因子《药物临床试验批准通知书》(通知书编号：2026LP02173)。本次获批为该产品完成核心生产工艺升级后的重新申报获批，不属于全新首次申报。本次人血管性血友病因子工艺升级后重新获批临床试验，是公司对该产品核心生产技术的重要优化，为临床试验顺利推进筑牢基础。本次获批临床试验事项将进一步激发研发团队创新积极性，完善公司在罕见出血性疾病领域的产品管线布局，为丰富血液制品产品线、强化核心市场竞争力提供有力支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0197","BK0239","300294","BMED","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652252257","title":"股市必读：博雅生物（300294）7月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2652252257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652252257?lang=zh_cn&edition=full","pubTime":"2026-07-20 01:24","pubTimestamp":1784481852,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，博雅生物报收于15.66元，下跌3.39%，换手率1.96%，成交量9.86万手，成交额1.57亿元。国内血液制品行业主流基础工艺为低温乙醇法，层析工艺主要用于后端精制环节以提升产品纯度。公司目前采用低温乙醇法联合层析纯化工艺生产10%静丙。交易信息汇总资金流向7月17日主力资金净流出1340.32万元，占总成交额0.0%；游资资金净流出663.21万元，占总成交额0.0%；散户资金净流入2003.53万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000000694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652403711","title":"博雅生物：采用低温乙醇法联合层析纯化工艺生产10%静丙","url":"https://stock-news.laohu8.com/highlight/detail?id=2652403711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652403711?lang=zh_cn&edition=full","pubTime":"2026-07-17 15:57","pubTimestamp":1784275031,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的技术路线什么时候能从\"低温乙醇\"切换到\"层析主导\"。博雅生物回复：您好，感谢您对本公司的关注。国内血液制品行业主流基础工艺为低温乙醇法，层析工艺主要用于后端精制环节以提升产品纯度。公司目前采用低温乙醇法（改良Cohn6法）联合层析纯化工艺生产10%静丙。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700028413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788384452352,"stockEarnings":[{"period":"1week","weight":-0.0351},{"period":"1month","weight":-0.0855},{"period":"3month","weight":-0.1079},{"period":"6month","weight":-0.3109},{"period":"1year","weight":-0.437},{"period":"ytd","weight":-0.3533}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0346},{"period":"3month","weight":-0.0287},{"period":"6month","weight":-0.0443},{"period":"1year","weight":0.0216},{"period":"ytd","weight":-0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32521人(较上一季度增加0.91%)","perCapita":"15505股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":"　　华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、凝血因子。公司获得了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}